Porton Warmly Congratulates Partner XZenith on Its Listing on the Main Board of the Hong Kong Stock Exchange

As an innovative enterprise deeply rooted in the biomedical field, XZenith has always been dedicated to the R&D, production, and commercialization of innovative drugs. The company has built a dual-drive R&D system covering both small-molecule and large-molecule drugs, strategically focusing on three core therapeutic areas: digestive system diseases, oncology, and non-alcoholic steatohepatitis (NASH). Currently, XZenith boasts three commercialized products and has established dedicated sales teams targeting digestive diseases and oncology, respectively. Meanwhile, it has more than ten projects under development, forming a diversified pipeline of innovative drugs.

XZenith's core products include:

• Anaprazole Sodium Enteric-coated Tablets (trade name: Anjiuwei®), China’s first self-developed PPI inhibitor approved for market launch.

• Bireociclib Tablets (trade name: Xuanyuening®), a novel CDK4/6 inhibitor for breast cancer treatment. It is the only innovative drug of its kind in China approved for monotherapy in patients with advanced, later-line breast cancer.

• Dirozalkib Tablets (trade name: Xuanfeining®), an anaplastic lymphoma kinase (ALK) inhibitor targeting ALK-positive non-small cell lung cancer.


Since 2018, Porton has been a key partner in XZenith's innovative drug R&D. Leveraging its professional and efficient CDMO service capabilities, Porton has provided end-to-end support covering R&D, production, and regulatory approval for market launch.
For the key drug Dirozalkib, Porton has been involved in full-lifecycle API services, including API supply during clinical phases, NDA-related research, process validation, registration inspection, GMP compliance inspection, and regulatory filing support. Through this full-process support, Porton has enabled efficient project progress, helping XZenith achieve milestones from clinical API supply to NDA acceptance.

In the Anaprazole Sodium project, Porton has engaged in GMP compliance inspection and commercial supply, as well as process optimization, NDA research, and PPQ production for the second supplier, and will continue to provide follow-up registration support. With a “Customer First” approach, Porton delivers each project through end-to-end CMC service. This support has ensured steady R&D and commercialization progress for the two innovative drugs above, enabling their successful market launch.

On this special occasion, Porton once again extends its warmest congratulations to XZenith. We look forward to seeing XZenith strengthen its leadership in the innovative drug field and achieve even greater success with the support of the global capital market. At the same time, Porton will also continue to empower more global innovative pharmaceutical companies with our high-quality CDMO services to enable the public's early access to good medicines.